UK-based pharmaceutical company Phagenesis closed its €7m ($9.3m) of series B funding yesterday with Inventages, a life sciences firm backed by Switzerland-based food and nutrition corporation Nestlé, leading the round.  Founded in 2007 after it span off from research performed at the University of Manchester, Phagenesis raised £2m ($3.1m) in a September 2010 series A round of financing from unnamed investors. Phagenesis is developing a device that will help dysphagia sufferers to swallow, using controlled electrical pulses. Gunnar Weikert, founder of Inventages, said: "Phagenesis is addressing a critical, unmet need in a very large market. Dysphagic patients are underserved by modern medicine and many face tube-feeding and a significant loss of quality of life for decades. Phagenesis is ideally placed to meet this challenge." Ashok Dhanrajgir, senior partner at Inventages, added: "We are optimistic that Phagenesis will demonstrate further clinical evidence on efficacy and health economic benefits to society."

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?